Literature DB >> 12959279

A clinical pharmacological assessment of doxazosin and enalapril in combination.

A D Bainbridge1, P A Meredith, H L Elliott.   

Abstract

This study in 12 normotensive males investigated potential pharmacokinetic and pharmacodynamic interaction mechanisms resulting from the combination of enalapril and doxazosin. Blood pressure reductions were consistently greater with the combination but there was no evidence of a significant pharmacodynamic interaction (as determined by heart rate changes, renal function tests or by pressor responsiveness indices) and there was no evidence of a pharmacokinetic interaction with either drug. Responsiveness to each drug i.e. blood pressure reduction per unit drug concentration was not significantly altered in the combination regimen. In conclusion, these results suggest that the combination of enalapril and doxazosin produces a usefully additive hypotensive effect but there was no evidence of synergism i.e an effect which was more than additive.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 12959279      PMCID: PMC1364667          DOI: 10.1111/j.1365-2125.1993.tb00421.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  Synergism between alpha 1-blockade and angiotensin converting enzyme inhibition in essential hypertension.

Authors:  M J Brown; J E Dickerson
Journal:  J Hypertens Suppl       Date:  1991-12

2.  Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: development of a mathematical model.

Authors:  R J Francis; A N Brown; L Kler; T Fasanella d'Amore; J Nussberger; B Waeber; H R Brunner
Journal:  J Cardiovasc Pharmacol       Date:  1987-01       Impact factor: 3.105

3.  Enhancement by an ACE inhibitor of first-dose hypotension caused by an alpha 1-blocker.

Authors:  T Baba; T Tomiyama; K Takebe
Journal:  N Engl J Med       Date:  1990-04-26       Impact factor: 91.245

4.  A pragmatic approach to the pressor dose-response as an index of vascular reactivity and adrenoceptor function in man.

Authors:  D J Sumner; H L Elliott; J Vincent; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1987-05       Impact factor: 4.335

5.  Determination of the vasodilator UK33274 by high-performance liquid chromatography using fluorescence detection.

Authors:  P C Rubin; J Brunton; P Meredith
Journal:  J Chromatogr       Date:  1980-11-14

6.  Simultaneous pharmacokinetic and pharmacodynamic modeling.

Authors:  W A Colburn
Journal:  J Pharmacokinet Biopharm       Date:  1981-06

7.  Facilitation of adrenergic transmission by locally generated angiotensin II in rat mesenteric arteries.

Authors:  K U Malik; A Nasjletti
Journal:  Circ Res       Date:  1976-01       Impact factor: 17.367

8.  Interactions between enalaprilat and doxazosin at rat tail artery alpha 1-adrenoceptors.

Authors:  J Marwood; G Tierney; G Stokes
Journal:  J Cardiovasc Pharmacol       Date:  1991-01       Impact factor: 3.105

9.  The effect of enalapril on baroreceptor mediated reflex function in normotensive subjects.

Authors:  J F Giudicelli; A Berdeaux; A Edouard; C Richer; D Jacolot
Journal:  Br J Clin Pharmacol       Date:  1985-09       Impact factor: 4.335

10.  Analysis of the pressor dose response.

Authors:  D J Sumner; H L Elliott; J L Reid
Journal:  Clin Pharmacol Ther       Date:  1982-10       Impact factor: 6.875

  10 in total
  1 in total

Review 1.  Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia.

Authors:  B Fulton; A J Wagstaff; E M Sorkin
Journal:  Drugs       Date:  1995-02       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.